Stocksigma LogoStocksigma Logo

Genpharmasec Reports Strong Q2 Results and Divestment of Clinigenome India

Genpharmasec reported consolidated revenue of ₹8,565.82 lakh for the quarter ended 30th Sep'26, up significantly from ₹3,263.71 lakh YoY and ₹4,971.03 lakh

Genpharmasec Reports Strong Q2 Results and Divestment of Clinigenome India

Genpharmasec Ltd · Financial Result · 03 Nov 2026, 11:02 pm

Genpharmasec Reports Strong Q2 Results and Divestment of Clinigenome India Genpharmasec reported consolidated revenue of ₹8,565.82 lakh for the quarter ended 30th Sep'26, up significantly from ₹3,263.71 lakh YoY and ₹4,971.03 lakh QoQ. Consolidated net profit swung to ₹102.92 lakh versus a net loss of ₹117.62 lakh in the prior-year period. In addition, the Board approved the complete divestment of wholly owned subsidiary Clinigenome India Private Limited to Micro Genomics India Private Limited by 31st Mar'27. Company Secretary Hardik Makwana tendered his resignation, effective 16th Nov'26.

Original exchange filing (PDF)

More announcements from Genpharmasec Ltd

All Genpharmasec Ltd announcements